The Wellness Group Announces Launch of Peptovation — A Next-Generation Peptide Platform Merging Science, Technology, and Human-Centric Design
The Wellness Group Announces Launch of Peptovation — A Next-Generation Peptide Platform Merging Science, Technology, and Human-Centric Design
Las Vegas, NV — June 30, 2025 — The Wellness Group today announced the official launch of Peptovation, a biotechnology company redefining peptide innovation through scientific rigor, advanced formulation technology, and a deep commitment to human-centric design.
Developed in partnership with Wellgineering.io, the R&D and venture studio funded by Coulson Capital, Peptovation unites world-class bioengineers, chemists, and formulation scientists to pioneer next-generation peptide delivery systems that improve efficacy, stability, and accessibility across both wellness and clinical-grade applications.
Science First
At the heart of Peptovation’s is a 30,000-square-foot, GMP-certified peptide manufacturing facility, designed to meet the most rigorous global standards of quality and consistency. Every product developed within the facility is subject to meticulous quality control, ensuring pharmaceutical-grade precision across the entire production process.
“At Peptovation, science comes first,” said Foster Coulson, Founder and CEO of The Wellness Group. “We’re not chasing trends — we’re building a new foundation for how peptides are formulated, delivered, and experienced. This is where biotechnology meets human design.”
Human-Centric Innovation
Peptovation’s mission extends beyond efficacy. Its research and development teams focus equally on ease of use, comfort, and accessibility, ensuring that advanced peptide technologies translate into real-world benefits for people, not just laboratories.
The company partnered with a proprietary Aquazome™ technology — a patented hybrid micelle–hydrocolloid delivery system — enables the transport of fragile actives at higher concentrations while bypassing the liver’s first-pass effect, dramatically enhancing bioavailability and stability.
Peptovation’s adaptable formulations support a range of delivery systems, including:
Oral films and dissolving strips for rapid uptake and ease of use
Transdermal patches for sustained release and consistent dosing
Advanced liquid suspensions designed for customizable clinical and wellness use
Specialized nutraceutical blends that merge science and supplementation
Global Reach and Collaboration
From wellness to clinical therapeutics, Peptovation’s platform is designed to scale globally — adaptable across industries, regulatory frameworks, and regional health markets.
Through its collaboration with Wellgineering, Peptovation is advancing the frontiers of peptide design, leveraging AI-driven modeling, molecular optimization, and predictive analytics to accelerate discovery and reduce time-to-market for new therapeutic formats.
“Our partnership with Wellgineering allows us to merge the precision of biotech with the creativity of venture science,” said Coulson. “Together, we’re building the next generation of bioactive technologies that improve life — from cellular health to global wellness.”
About Peptovation
Peptovation is a science-first biotechnology company pioneering the next generation of peptide formulations and delivery systems. Backed by The Wellness Group, Peptovation operates in a 30,000-square-foot GMP-certified manufacturing facility dedicated to developing oral, transdermal, and liquid peptide formats powered by Aquazome™ hybrid micelle–hydrocolloid technology for superior bioavailability and stability.
About The Wellness Group
The Wellness Group is a health and human services organization dedicated to improving population health through innovative solutions that integrate clinical care, behavioral health, wellness, and pharmacy services.
About Wellgineering
Wellgineering.io is a research lab and venture studio backed by Coulson Capital and The Wellness Group, bringing together elite scientists and engineers to develop and incubate breakthrough technologies at the intersection of biotech and artificial intelligence.